EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSPREG00000005481
Gene Symbol: GRIK3
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSPREG00000022237
Gene Symbol: GRIK4
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPREG00000013939
Gene Symbol: GRIK5
3 Cross references
230 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPREG00000017826
Gene Symbol: GRIK5
3 Cross references
229 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSPREG00000009482
Gene Symbol: GRM2
3 Cross references
206 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPREG00000012856
Gene Symbol: GRM4
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPREG00000005310
Gene Symbol: GRM4
3 Cross references
196 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSPREG00000020546
Gene Symbol: GRM5
3 Cross references
214 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSPREG00000021413
Gene Symbol: LOC103473962
3 Cross references
205 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2a-Like

Ensembl ID : ENSPREG00000000053
Gene Symbol: LOC103462623
2 Cross references
98 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2b-Like

Ensembl ID : ENSPREG00000012832
Gene Symbol: LOC103468798
3 Cross references
250 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSPREG00000000885
Gene Symbol: LOC103472853
2 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).